Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL. Trebeschi S, et al. Among authors: lalezari f. Ann Oncol. 2019 Jun 1;30(6):998-1004. doi: 10.1093/annonc/mdz108. Ann Oncol. 2019. PMID: 30895304 Free PMC article.
Optimal endobronchial tool sizes for targeting lung lesions based on 3D modeling.
Bydlon TM, Langhout GC, Lalezari F, Hartemink KJ, Nijkamp J, Brouwer de Koning SG, Burgers S, Hendriks BHW, Ruers TJM. Bydlon TM, et al. Among authors: lalezari f. PLoS One. 2017 Dec 19;12(12):e0189963. doi: 10.1371/journal.pone.0189963. eCollection 2017. PLoS One. 2017. PMID: 29261769 Free PMC article.
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P. Quispel-Janssen J, et al. Among authors: lalezari f. J Thorac Oncol. 2018 Oct;13(10):1569-1576. doi: 10.1016/j.jtho.2018.05.038. Epub 2018 Jun 14. J Thorac Oncol. 2018. PMID: 29908324 Free article. Clinical Trial.
The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases.
van der Werf LR, Wassenaar E, de Niet A, Lalezari F, Braam HJ, van Ramshorst B, Nederend J, de Hingh IHJT, Kok NFM, Aalbers AGJ. van der Werf LR, et al. Among authors: lalezari f. Eur J Surg Oncol. 2019 Mar;45(3):376-382. doi: 10.1016/j.ejso.2018.10.540. Epub 2018 Nov 1. Eur J Surg Oncol. 2019. PMID: 30414704
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: lalezari f. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Nat Med. 2019. PMID: 31086347 Clinical Trial.
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: lalezari f. Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5. Nat Med. 2019. PMID: 31209337
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, Lalezari F, Reeves J, Warren S, van Thienen JV, van Tinteren H, Haanen JBAG, Kapiteijn E, Blank CU. Rozeman EA, et al. Among authors: lalezari f. Melanoma Res. 2020 Jun;30(3):252-260. doi: 10.1097/CMR.0000000000000653. Melanoma Res. 2020. PMID: 31895753 Clinical Trial.
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, Blank CU, Haanen JBAG, Powles T, Bex A. Meerveld-Eggink A, et al. Among authors: lalezari f. Eur Urol Open Sci. 2022 Jan 3;35:54-58. doi: 10.1016/j.euros.2021.11.003. eCollection 2022 Jan. Eur Urol Open Sci. 2022. PMID: 35024632 Free PMC article.
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K, Thommen DS. Hummelink K, et al. Among authors: lalezari f. Clin Cancer Res. 2022 Nov 14;28(22):4893-4906. doi: 10.1158/1078-0432.CCR-22-0992. Clin Cancer Res. 2022. PMID: 35852792 Free PMC article.
30 results